retatrutide clinical trial information Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Retatrutide Dosing: Early Clinical Trial

In the retatrutide Phase 2 trial, high-sensitivity CRP fell alongside body weight [1], which mechanistically predicts improved central androgen signaling even before peripheral hormone levels are measured

Weight loss injections are to be given once a week

Benefits Timeline Week 1-2: Food noise reduction, quieting of cravings begins Month 1: 2-4 pound loss typical, nausea under 10% for microdosers Month 3: 5-8% total body weight loss sustained Microdosing can support natural satiety and mindful eating, making it easier to build sustainable healthy habits rather than relying solely on the medication

For researchers focused primarily on metabolic markers, the 4mg to 8mg range appears to provide strong metabolic benefit with a favorable side effect profile